Nuclear DNA sensor IFI16 as circulating protein in autoimmune diseases is a signal of damage that impairs endothelial cells through high-affinity membrane binding

PLoS One. 2013 May 14;8(5):e63045. doi: 10.1371/journal.pone.0063045. Print 2013.

Abstract

IFI16, a nuclear pathogenic DNA sensor induced by several pro-inflammatory cytokines, is a multifaceted protein with various functions. It is also a target for autoantibodies as specific antibodies have been demonstrated in the sera of patients affected by systemic autoimmune diseases. Following transfection of virus-derived DNA, or treatment with UVB, IFI16 delocalizes from the nucleus to the cytoplasm and is then eventually released into the extracellular milieu. In this study, using an in-house capture enzyme-linked immunsorbent assay we demonstrate that significant levels of IFI16 protein can also exist as circulating form in the sera of autoimmune patients. We also show that the rIFI16 protein, when added in-vitro to endothelial cells, does not affect cell viability, but severely limits their tubulogenesis and transwell migration activities. These inhibitory effects are fully reversed in the presence of anti-IFI16 N-terminal antibodies, indicating that its extracellular activity resides within the N-terminus. It was further demonstrated that endogenous IFI16 released by apoptotic cells bind neighboring cells in a co-culture. Immunofluorescence assays revealed existence of high-affinity binding sites on the plasma membrane of endothelial cells. Free recombinant IFI16 binds these sites on HUVEC with dissociation constant of 2.7 nM, radioiodinated and unlabeled IFI16 compete for binding sites, with inhibition constant (Ki) of 14.43 nM and half maximal inhibitory concentration (IC50) of 67.88 nM; these data allow us to estimate the presence of 250,000 to 450,000 specific binding sites per cell. Corroborating the results from functional assays, this binding could be completely inhibited using anti-IFI16 N-terminal antibody, but not with an antibody raised against the IFI16 C-terminal. Altogether, these data demonstrate that IFI16 may exist as circulating protein in the sera of autoimmune patients which binds endothelial cells causing damage, suggesting a new pathogenic and alarmin function through which this protein triggers the development of autoimmunity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / immunology
  • Autoimmune Diseases / blood
  • Autoimmune Diseases / metabolism
  • Autoimmune Diseases / pathology*
  • Cell Membrane / metabolism*
  • Cell Movement
  • Cell Nucleus / genetics*
  • DNA / metabolism*
  • Down-Regulation
  • Enzyme-Linked Immunosorbent Assay
  • Extracellular Space / metabolism
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Human Umbilical Vein Endothelial Cells / pathology*
  • Kinetics
  • Nuclear Proteins / blood*
  • Nuclear Proteins / immunology
  • Nuclear Proteins / metabolism*
  • Phosphoproteins / blood*
  • Phosphoproteins / immunology
  • Phosphoproteins / metabolism*

Substances

  • Antibodies, Neutralizing
  • Nuclear Proteins
  • Phosphoproteins
  • IFI16 protein, human
  • DNA

Grants and funding

This study was supported by MIUR PRIN 2008 (Ministero dell’Istruzione, dell’Università e della Ricerca - Progetti di Ricerca di Interesse Nazionaleto) to SL, MG and AT, and research funding from the University of Turin 2011 to SL. VC acknowledges a grant for the Lagrange Project-CRT Foundation. MB is a recipient of an international PhD fellowship in Innovative Biomedical Technologies (IBT) funded by Cariplo Foundation-Milan, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.